pancreatic neuroendocrine tumor: Pancreatic endocrine tumor, also known as pancreatic neuroendocrine tumor (PNET), describes a group of endocrine tumors originating in the pancreas that are usually indolent and benign, but may have the potential to be malignant. They can be functional, exhibiting a hormonal hypersecretion syndrome, but can be non-functional presenting with non-specific symptoms and include insulinoma, glucagonoma, VIPoma, somatostatinoma (SSoma), PPoma and Zollinger-Ellison syndrome (ZES, or gastrinoma) and other ectopic hormone producing tumors (such as GRFoma) (see these terms).
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
246 |
4. Check minimum number of eventsNone |
246 |
5. Include endpointsNone |
246 |
6. Filter based on genotype QC (FinnGen only) |
221 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D13
- Name in latin
- Neoplasma benignum partis endocrinae pancreatis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Endocrine pancreas
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of other and ill-defined parts of digestive system
- Benign neoplasms
- Neoplasms
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 826 | 449 | 372 |
| Only index persons | 764 | 421 | 343 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.35 | 64.03 | 64.77 |
| Only index persons | 63.60 | 62.65 | 64.76 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 221 | 101 | 120 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.06 |
| Median age at first event (years) | 64.15 | 61.26 | 66.57 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 227
- Matched controls
- 2270
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D13.7
ICD-10 Finland
Benign neoplasm: Endocrine pancreas
+∞
309.0
220
*
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
59.9
167.7
101
30
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
38.4
79.4
51
17
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
21.3
60.9
49
29
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
16.1
41.8
38
28
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
17.6
41.7
36
24
WX302
NOMESCO Finland
Thoracal epidural anesthesy
9.1
34.5
47
63
JN3BD
NOMESCO Finland
Extensive abdominal CT
6.1
30.2
64
137
D13.6
ICD-10 Finland
Benign neoplasm: Pancreas
76.7
29.8
33
5
JLC10
NOMESCO Finland
Distal pancreatectomy
305.2
27.3
27
*
JN3AD
NOMESCO Finland
Abdominal CT examination
5.1
26.9
73
193
C25.4
ICD-10 Finland
Malignant neoplasm: Endocrine pancreas
+∞
23.3
22
*
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
39.9
20.3
25
7
8240/3-C25.9
ICD-O-3
Neuroendocrine tumor, NOS, of pancreas, NOS
+∞
19.0
18
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.2
18.5
43
98
H01CB03
ATC
lanreotide; parenteral
72.7
18.0
20
*
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
19.0
17.9
27
16
JLC00
NOMESCO Finland
Excision of lesion of pancreas
+∞
15.8
15
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.1
15.1
48
139
E16.2
ICD-10 Finland
Hypoglycaemia, unspecified
23.0
15.0
21
10
D44.8
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pluriglandular involvement
85.8
14.8
16
*
E16.10
ICD-10 Finland
Hyperinsulinism
+∞
14.7
14
*
JLC11
NOMESCO Finland
Laparoscopic distal pancreatectomy
+∞
14.7
14
*
JJ1CE
NOMESCO Finland
Liver, bile duct and pancreas endoscopic ultrasound examination
38.9
14.7
18
5
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.0
14.6
114
576
K86.2
ICD-10 Finland
Cyst of pancreas
20.9
14.5
21
11
WX408
NOMESCO Finland
General anesthesy, balanced
3.0
14.0
90
407
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
12.1
13.4
24
22
JN1BD
NOMESCO Finland
Extensive CT examination of upper part of abdomen
42.9
13.3
16
*
JL5AG
NOMESCO Finland
Simple MRI examinaiton of bile and pancreas ducts with high intesity magnet
18.1
13.2
20
12
XJD02
NOMESCO Finland
Peroral endoscopic ultrasonography
20.6
13.2
19
10
JN4CD
NOMESCO Finland
Very extensive body CT
6.0
12.9
24
44
JL5BG
NOMESCO Finland
MRI examinaiton of bile and pancreas ducts with high intesity magnet
10.2
12.3
24
26
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.4
11.9
32
81
K86.9
ICD-10 Finland
Disease of pancreas, unspecified
31.9
11.8
15
5
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.0
11.1
35
100
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
16.6
11.0
17
11
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
16.6
11.0
17
11
WX402
NOMESCO Finland
General anaesthesia
2.8
10.9
75
344
JN4AD
NOMESCO Finland
Body CT examination
3.2
10.8
51
190
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
10.6
93
481
C25.2
ICD-10 Finland
Malignant neoplasm: Tail of pancreas
+∞
10.5
10
*
8249/3-C25.9
ICD-O-3
Neuroendocrine tumor, grade 2 of pancreas, NOS
+∞
10.5
10
*
130
Kela drug reimbursment
Malignant tumour
3.4
10.4
42
142
JLC30
NOMESCO Finland
Pancreatoduodenectomy
24.7
10.4
14
6
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
16.0
9.7
15
10
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
9.3
46
175
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
9.3
50
200
E21.0
ICD-10 Finland
Primary hyperparathyroidism
10.7
9.2
17
17
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
25.2
9.0
12
5
ZXE10
NOMESCO Finland
More than one and less than three hours
2.3
8.8
103
596
E34.0
ICD-10 Finland
Carcinoid syndrome
52.0
8.7
10
*
BBA50
NOMESCO Finland
Total parathyroidectomy
+∞
8.4
8
*
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
18.0
8.2
12
7
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
10.6
8.2
15
15
D76
ICPC
Malignant neoplasm pancreas
34.7
8.1
10
*
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
23.0
8.1
11
5
JN4BD
NOMESCO Finland
Extensive body CT
2.9
8.0
43
171
JN1BG
NOMESCO Finland
MRI examination of upper part of abodmen with high intensity magnet
12.4
7.7
13
11
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
2.9
7.6
38
145
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.3
7.4
79
434
E21.2
ICD-10 Finland
Other hyperparathyroidism
+∞
7.3
7
*
R93.3
ICD-10 Finland
Abnormal findings on diagnostic imaging of other parts of digestive tract
31.1
7.2
9
*
H01CB02
ATC
octreotide; parenteral
31.1
7.2
9
*
E66.8
ICD-10 Finland
Other obesity
4.5
7.2
18
43
JAH01
NOMESCO Finland
Laparoscopy
4.4
7.0
18
44
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
8.7
6.9
14
17
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
8.2
6.7
14
18
Z01.8
ICD-10 Finland
Other specified special examinations
2.2
6.5
66
352
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.3
6.4
57
288
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.1
6.4
77
441
2117X
ICD-9 Finland
Benign neoplasm of other parts of digestive system, Islets of Langerhans[NEOPLASMA BENIGNUM ALIUD INSULARUM LANGERHANS]
+∞
6.3
6
*
V03AH01
ATC
diazoxide; systemic
+∞
6.3
6
*
BBA70
NOMESCO Finland
Implantation or transplantation of parathyroid gland
+∞
6.3
6
*
T73
ICPC
Neoplasm endocrine other/unspecified
+∞
6.3
6
*
8240/3-C25.2
ICD-O-3
Neuroendocrine tumor, NOS, of tail of pancreas
+∞
6.3
6
*
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.3
6.2
56
285
JN1AD
NOMESCO Finland
CT examination of upper part of abdomen
13.0
6.1
10
8
T90
ICPC
Diabetes non-insulin dependent
2.1
6.1
77
446
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
6.1
133
939
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
64
98
8.70
42.50
2.5
3.3
31.15
2155.43
u/ml
0.83
54
83
52
66
9.92
40.08
1.8
1.4
217.70
298.21
ug/g
1.44
41
40
97
245
6.17
39.31
3.3
4.9
2.81
25.27
ug/l
0.75
71
210
148
706
4.15
23.94
4.0
2.7
68.27
68.10
u/l
0.01
143
657
72
216
4.42
22.28
3.2
2.6
231.33
32.61
u/l
0.55
63
176
173
986
4.17
20.14
7.6
5.1
34.72
35.39
g/l
0.88
168
937
173
1016
3.95
18.56
8.9
6.6
1.21
1.21
mmol/l
0.25
165
942
179
1115
3.86
16.64
12.2
7.5
1.21
1.21
mmol/l
0.08
147
966
172
1067
3.53
15.60
18.0
14.5
1.18
1.26
inr
1.52
144
875
69
267
3.28
14.01
2.6
3.5
8.07
7.98
umol/l
0.01
59
240
53
174
3.67
13.92
5.0
3.7
91.93
80.67
ng/l
0.48
45
149
77
341
2.90
12.15
7.3
7.2
105.78
103.74
mmol/l
4.23
77
341
66
280
2.91
11.16
8.4
7.8
5.08
5.13
kpa
0.17
66
271
121
714
2.49
10.33
3.4
3.3
27.03
32.64
u/l
1.51
115
678
146
944
2.53
10.14
3.4
2.4
82.01
76.68
nmol/l
1.27
139
830
112
664
2.36
9.14
3.4
3.4
1.34
0.58
e6/l
0.30
85
481
146
982
2.36
8.73
3.8
2.9
—
—
estimate
—
0
0
78
411
2.37
8.17
2.9
3.1
0.82
0.82
mmol/l
0.13
78
392
126
815
2.23
8.02
3.5
3.5
—
—
—
0
0
46
197
2.67
7.42
4.3
4.4
1.22
1.23
mmol/l
0.12
38
175
116
762
2.07
6.71
3.7
3.4
6.61
7.74
mmol/l
2.58
102
632
35
139
2.79
6.49
10.4
9.0
16.55
15.76
%
0.88
35
134
114
751
2.04
6.47
4.6
4.3
11.90
8.22
mg/mmol
0.39
75
489
162
1234
2.09
5.91
11.2
10.0
4.53
4.22
e9/l
0.95
144
1072
175
1375
2.19
5.84
5.2
4.9
—
423.52
—
0
27
49
252
2.20
5.21
5.3
3.5
—
—
—
0
0
150
1153
1.89
4.82
4.7
4.1
0.00
5.97
estimate
0.50
46
272
75
464
1.92
4.80
3.7
2.9
2.50
2.46
mmol/l
1.88
68
410
62
364
1.97
4.60
3.0
3.3
0.96
2.05
e6/l
1.06
25
173
150
1163
1.85
4.58
4.7
4.2
0.53
1.21
estimate
0.22
44
251
13
27
5.04
4.57
1.3
1.5
—
—
—
0
0
147
1137
1.83
4.47
4.7
4.1
0.00
0.00
estimate
-0.00
46
261
32
154
2.25
3.96
1.9
1.5
—
—
—
0
0
64
404
1.81
3.73
3.0
3.1
0.86
1.14
e6/l
0.28
27
210
180
1523
1.88
3.65
5.0
4.2
14.77
14.97
pmol/l
0.48
168
1375
119
904
1.66
3.51
4.4
4.1
36.73
40.27
ng/l
0.12
90
696
164
1364
1.73
3.35
5.4
3.4
65.04
50.79
u/l
0.61
157
1275
48
286
1.86
3.34
1.9
2.0
—
—
—
0
0
116
885
1.64
3.30
2.2
2.0
1.51
1.35
mmol/l
1.03
100
720
126
983
1.63
3.26
2.3
2.1
93.78
96.63
pmol/l
0.31
74
520
11
29
3.93
3.23
1.1
1.1
—
21.00
—
0
5
94
684
1.64
3.21
1.7
1.7
23.86
20.88
nmol/l
1.16
85
562
214
1954
2.66
3.14
7.4
5.4
6.52
6.03
mmol/l
3.04
207
1796
93
678
1.63
3.13
2.1
2.2
171.10
213.56
u/l
0.35
88
642
49
302
1.79
3.05
1.8
1.9
—
—
—
0
0
16
63
2.66
3.03
1.2
1.5
—
—
—
0
0
74
513
1.66
3.02
3.4
2.5
—
—
—
0
0
59
388
1.70
2.93
1.9
2.1
—
—
—
0
0
100
752
1.59
2.92
3.1
3.5
1404.43
1343.91
ng/l
0.06
84
633
211
1925
2.36
2.91
10.3
6.9
42.17
40.00
mmol/mol
2.17
203
1809
25
124
2.14
2.89
1.4
1.8
—
—
—
0
0
63
424
1.67
2.87
5.6
4.2
246.00
212.35
ng/l
0.10
53
345
29
155
2.00
2.77
10.5
6.3
24.01
24.65
mmol/l
0.35
29
148
82
597
1.58
2.70
2.6
3.1
386.91
351.07
umol/l
1.66
64
519
203
1840
1.98
2.61
6.0
5.3
1.94
1.95
mu/l
0.04
190
1679
214
1981
2.40
2.54
27.9
17.8
32.35
24.08
mg/l
2.39
201
1656
21
103
2.14
2.51
2.4
1.9
7.65
4.90
ug/l
0.21
21
94
14
57
2.55
2.50
1.2
1.4
—
—
—
0
0
55
375
1.62
2.35
2.4
1.7
1296.22
1246.55
nmol/l
0.14
46
288
68
488
1.56
2.34
1.7
1.8
2.16
1.60
mg/l
0.40
53
388
84
632
1.52
2.34
4.4
3.6
0.00
0.12
estimate
0.52
37
216
109
869
1.49
2.28
4.9
4.2
0.00
0.00
estimate
-0.00
38
221
8
24
3.42
2.20
1.0
1.3
—
—
—
0
0
65
472
1.53
2.10
2.1
1.8
442.92
444.73
pmol/l
0.02
52
387
13
56
2.40
2.09
4.6
2.7
12.42
8.58
pmol/l
0.47
13
56
217
2042
2.42
2.08
36.8
21.1
139.64
139.63
mmol/l
0.01
217
2008
176
1563
1.56
2.08
5.3
4.5
13.56
12.68
mm/h
0.34
163
1445
217
2043
2.41
2.06
36.9
21.3
3.97
3.99
mmol/l
0.45
217
2007
8
27
3.03
1.95
1.0
1.2
—
—
—
0
0
6
17
3.60
1.85
1.7
1.2
—
—
—
0
0
5
12
4.23
1.83
4.2
7.6
—
—
—
0
0
5
12
4.23
1.83
2.6
1.7
—
—
—
0
0
17
90
1.96
1.70
2.0
4.8
39.11
114.29
mg/l
0.58
11
76
17
90
1.96
1.70
2.0
4.8
34.84
29.77
mg/l
0.25
11
77
16
83
2.00
1.69
1.9
4.4
1.58
2.60
ratio
—
6
42
7
25
2.86
1.66
1.4
1.2
—
—
—
0
0
19
106
1.86
1.64
1.7
2.4
3.73
3.90
g/l
0.16
19
100
19
106
1.86
1.64
1.8
2.4
4.25
4.36
g/l
0.22
19
100
19
106
1.86
1.64
1.8
2.4
6.87
7.55
g/l
1.61
19
100
5
14
3.63
1.62
1.0
1.1
—
—
—
0
0
5
14
3.63
1.62
1.0
1.1
—
—
—
0
0
5
14
3.63
1.62
1.4
1.1
—
—
—
0
0
12
57
2.17
1.58
1.7
1.5
—
—
—
0
0
18
102
1.83
1.50
1.8
2.4
2.68
3.11
g/l
1.53
18
96
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
73
1.98
1.47
1.9
2.2
0.39
0.42
iu/ml
—
5
40
13
67
2.00
1.41
1.2
1.2
—
—
—
0
0
34
234
1.53
1.40
3.3
3.8
1.24
1.96
mmol/l
0.34
29
198
112
954
1.34
1.40
3.7
3.0
141.25
138.41
ug/l
0.04
107
881
62
483
1.39
1.36
1.3
1.3
0.83
1.20
u/ml
0.57
15
141
82
669
1.35
1.35
5.0
4.1
0.00
0.00
estimate
-0.00
40
246
16
91
1.82
1.33
1.9
2.5
9.77
10.08
g/l
0.14
16
84
15
84
1.84
1.30
2.2
2.9
—
—
—
0
0
5
18
2.82
1.29
1.6
1.2
—
—
—
0
0
9
44
2.09
1.28
1.9
7.2
—
134.50
—
0
6
6
25
2.44
1.25
1.3
1.2
—
—
—
0
0
218
2102
1.94
1.24
39.1
23.5
85.05
80.72
umol/l
0.68
218
2084
27
182
1.55
1.23
2.6
3.2
60.32
60.15
ml/min/173m2
0.01
14
84
5
19
2.67
1.22
1.6
1.2
—
—
—
0
0
5
19
2.67
1.22
1.6
1.2
—
—
—
0
0
5
19
2.67
1.22
1.6
1.2
—
—
—
0
0
20
126
1.64
1.19
1.5
1.3
—
—
—
0
0
5
20
2.53
1.15
2.2
3.6
318.40
524.45
mg
—
5
20
11
58
1.94
1.14
1.0
1.8
—
—
—
0
0
5
21
2.41
1.09
1.6
1.6
—
—
—
0
0
7
33
2.16
1.06
3.0
4.0
—
—
—
0
0
5
22
2.30
1.04
1.6
1.2
—
—
—
0
0
15
93
1.66
0.96
1.9
2.8
0.83
0.75
g/l
0.05
15
85
11
64
1.76
0.88
1.4
1.3
—
2.84
—
0
10
6
30
2.03
0.87
2.7
3.3
1.19
1.19
mmol/l
—
6
30
6
31
1.96
0.85
2.7
3.2
107.33
106.19
mmol/l
—
6
31
6
32
1.90
0.82
1.5
2.6
10.67
11.13
mmol/l
—
6
32
6
32
1.90
0.82
1.5
1.5
—
—
—
0
0
0
24
0.00
0.79
0.0
1.5
—
1.44
—
0
11
0
24
0.00
0.79
0.0
1.5
—
0.90
—
0
11
0
24
0.00
0.79
0.0
1.5
—
1.03
—
0
11
126
1145
1.23
0.78
2.8
2.9
—
—
—
0
0
6
34
1.78
0.77
1.5
1.7
—
—
—
0
0
13
83
1.60
0.76
2.1
2.6
0.00
0.00
g/l
-0.00
13
75
13
83
1.60
0.76
2.1
2.6
0.22
0.00
g/l
0.47
13
78
19
133
1.47
0.76
2.4
2.7
0.67
0.63
%
0.22
19
133
9
55
1.66
0.74
1.7
1.3
—
—
—
0
0
7
38
1.87
0.74
1.1
3.8
—
5127.40
u/ml
—
0
5
7
41
1.73
0.70
2.1
3.3
11.29
35.20
u/ml
—
7
41
15
102
1.50
0.69
1.2
1.3
177.33
153.31
u/ml
—
6
38
8
49
1.66
0.63
1.1
1.5
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
160.63
—
0
20
27
211
1.32
0.60
1.9
2.7
12.82
13.05
nmol/l
0.06
22
193
13
89
1.49
0.59
3.8
2.0
307.69
327.41
ug/l
0.03
13
83
24
186
1.32
0.57
1.4
1.4
—
—
—
0
0
218
2137
1.51
0.53
45.5
27.0
130.96
135.39
g/l
3.96
218
2116
218
2137
1.51
0.53
46.4
27.3
39.32
40.42
%
2.18
218
2118
218
2137
1.51
0.53
45.1
26.8
4.37
4.49
e12/l
2.77
218
2088
218
2136
1.52
0.53
45.1
26.8
246.75
242.68
e9/l
0.37
218
2099
218
2136
1.52
0.53
45.0
26.7
91.56
91.48
fl
0.09
218
2118
16
118
1.38
0.52
11.9
4.2
1.61
1.54
%
0.22
16
110
56
488
1.20
0.51
4.4
4.5
1.02
1.02
kg/l
0.04
46
329
17
127
1.37
0.51
6.9
4.1
0.84
1.88
mmol/l
—
10
93
7
46
1.54
0.48
1.1
1.2
—
13.77
—
0
6
95
877
1.14
0.42
6.8
5.9
2.08
2.85
ug/l
0.79
86
789
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
4.0
—
1.00
—
0
15
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.7
—
—
—
0
0
8
61
1.32
0.40
1.0
1.2
—
—
—
0
0
8
61
1.32
0.40
1.5
1.5
—
—
—
0
0
6
43
1.41
0.35
1.2
1.3
—
—
—
0
0
6
43
1.41
0.35
1.2
1.3
—
—
—
0
0
202
1976
1.20
0.33
5.9
5.4
1.34
1.45
mmol/l
3.55
193
1818
10
74
1.37
0.33
1.4
1.7
—
—
—
0
0
6
47
1.28
0.32
1.5
1.8
—
—
—
0
0
7
54
1.31
0.30
1.1
1.2
—
—
—
0
0
7
57
1.24
0.29
1.4
1.7
—
—
—
0
0
8
62
1.30
0.28
1.0
1.2
—
—
—
0
0
202
1984
1.16
0.25
6.2
5.5
4.25
4.53
mmol/l
3.22
193
1837
9
76
1.19
0.25
9.7
4.7
24.21
25.33
mmol/l
—
9
71
0
11
0.00
0.21
0.0
3.8
—
5.09
—
0
11
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
3.8
—
9.95
—
0
11
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
6
48
1.26
0.20
1.5
1.8
—
—
—
0
0
6
49
1.23
0.20
1.0
1.1
—
3.13
—
0
6
6
50
1.21
0.20
1.3
1.4
—
—
—
0
0
5
66
0.75
0.17
1.0
1.1
1.62
1.56
g/l
—
5
66
5
69
0.72
0.17
1.0
1.1
0.75
0.85
g/l
—
5
69
26
235
1.12
0.16
1.3
1.4
—
—
—
0
0
9
78
1.16
0.15
1.4
1.7
—
—
—
0
0
56
529
1.08
0.15
4.3
3.5
0.84
0.79
ug/l
0.21
47
355
192
1894
1.09
0.14
5.0
4.6
1.40
1.27
mmol/l
1.73
180
1728
13
113
1.16
0.13
1.3
2.1
1.74
1.51
g/l
0.77
13
99
16
146
1.10
0.08
1.3
1.7
—
—
—
0
0
39
372
1.06
0.08
1.2
1.3
24.56
29.76
iu/ml
—
10
128
7
64
1.10
0.08
1.4
1.7
—
—
—
0
0
203
2015
1.07
0.07
7.1
6.3
2.46
2.62
mmol/l
1.75
194
1864
8
95
0.84
0.07
1.0
1.3
—
—
—
0
0
29
303
0.95
0.05
1.7
1.5
—
—
—
0
0
10
91
1.10
0.04
1.2
1.0
—
—
—
0
0
24
250
0.96
0.03
16.6
7.8
—
—
—
0
0
14
134
1.05
0.00
1.2
1.2
82.74
310.01
u/ml
0.99
14
122
71
704
1.01
0.00
4.6
4.9
20.05
21.36
%
0.44
45
358
16
161
0.99
0.00
1.4
1.9
—
—
—
0
0
7
73
0.96
0.00
2.4
2.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
174.00
—
0
5
6
59
1.02
-0.00
1.2
1.3
—
—
—
0
0
6
63
0.95
-0.00
1.2
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
70
1.00
-0.00
2.4
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
1.17
—
0
5
7
72
0.97
-0.00
1.3
1.9
—
—
—
0
0
34
340
1.00
-0.00
1.1
1.3
1.23
8.69
u/ml
2.21
18
133
6
65
0.92
-0.00
1.3
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
5
50
1.00
-0.00
1.6
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_ENDOCRINE_PANCREAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_PANCREAS | 2.501 [1.71, 3.67] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.048 |
During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 343 females with CD2_BENIGN_ENDOCRINE_PANCREAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_PANCREAS | 2.53 [1.48, 4.32] | < 0.001 |
| Birth year | 0.985 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 73 out of 275 males with CD2_BENIGN_ENDOCRINE_PANCREAS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_ENDOCRINE_PANCREAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.26% | 0.423% |
| 5 | 1.356% | 2.896% |
| 10 | 3.129% | 6.819% |
| 15 | 6.062% | 13.219% |
| 20 | 10.476% | 20.537% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_ENDOCRINE_PANCREAS – Benign neoplasm: Endocrine pancreas
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data